Table 1 Demographic and Baseline Characteristics

Sex, n (%)

0.389

 Female

14(28)

35(35)

 Male

36(72)

65(65)

Age, yr, mean (SD)

31.02(15.00)

58.52(13.22)

< 0.0001*

BMI(Kg/m2), median (IQR)

24.22(23.39–26.23)

24.22(23.43–26.03)

0.484

Hypertension, n (%)

12(24)

55(55)

< 0.001*

Diabetes, n (%)

4(8)

12(12)

0.454

Hematoma location, n (%)

N/A

 Basal ganglia

N/A

45(45)

 Lobar

N/A

14(14)

 Thalamus

N/A

26(26)

 Cerebellum

N/A

6(6)

 Brainstem

N/A

3(3)

 Ventricle

N/A

6(6)

Into the ventricle, n (%)

N/A

45(45)

N/A

Final ICH volume(ml), n (%)

N/A

 < 30

N/A

52(52)

 ≥ 30

N/A

48(48)

Hydrocephalus, n (%)

N/A

16(16)

N/A

GCS, median (IQR)

N/A

9(5–12)

N/A

Time from symptom onset to MIS (hours), mean (SD)

N/A

4.15(3.62)

N/A

Infection while in hospital, n (%)

N/A

27(27)

N/A

Routine examination of CSF

 WBC(n), median (IQR)

3(2–6)

20(6-233)

< 0.0001*

 RBC(n), median (IQR)

6(3.75-10)

3580(212.5-13100)

< 0.0001*

Biochemical reactions of CSF

 PRO(g/L), median (IQR)

0.245(0.190–0.310)

1.10(0.53–2.20)

< 0.0001*

 GLU (mmol/L), median (IQR)

3.315(3.133–3.603)

3.830(3.180–5.640)

< 0.001*

 CL (mmol/L), median (IQR)

121.4(120.4-122.8)

122.5(117.6-127.3)

0.471

GOS, n (%)

N/A

 1 ~ 3

N/A

53(53)

 4 ~ 5

N/A

47(47)